论文部分内容阅读
目的观察苯磺酸氨氯地平和氯沙坦联合治疗原发性高血压的临床疗效。方法选择2007年1月—2010年6月门诊治疗的原发性高血压患者120例,随机分为氯沙坦组(A组,口服氯沙坦50 mg、1次/d);氯沙坦+苯磺酸氨氯地平组(B组,氯沙坦50 mg+苯磺酸氨氯地平5 mg,1次/d),疗程为4周。比较2组治疗4周后药物的有效性及安全性。结果在原发性高血压患者中B组比A组的血压进一步下降,差异有统计学意义(P<0.05)。A组总有效率78.3%,B组总有效率93.3%,差异具有统计学意义(P<0.01)。结论原发性高血压患者采用苯磺酸氨氯地平和氯沙坦联合治疗有效率优于单用氯沙坦,疗效确切、安全,无明显不良反应,适合临床应用。
Objective To observe the clinical efficacy of amlodipine besylate combined with losartan in the treatment of essential hypertension. Methods One hundred and twenty patients with essential hypertension treated in clinic from January 2007 to June 2010 were randomly divided into losartan group (group A, losartan 50 mg once daily), losartan + Amlodipine besylate group (group B, losartan 50 mg + amlodipine besylate 5 mg once daily) for 4 weeks. The effectiveness and safety of the drugs were compared between the two groups after 4 weeks of treatment. Results Compared with group A, the blood pressure of group B was further decreased in patients with essential hypertension, the difference was statistically significant (P <0.05). The total effective rate was 78.3% in group A and 93.3% in group B, the difference was statistically significant (P <0.01). Conclusion The combination therapy of amlodipine besylate and losartan is superior to losartan alone in patients with essential hypertension. The curative effect is exact, safe and no obvious adverse reactions, which is suitable for clinical application.